Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

Stifel Nicolaus analyst Adam Borg maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $200.00. The company’s shares opened today at $194.57. Borg covers the ...

In a report released today, Jason Celino from KeyBanc maintained a Buy rating on PTC (PTC – Research Report). The company’s shares closed yesterday at $198.04. Celino covers the Technology ...

PTC Therapeutics (NASDAQ:PTCT) shares plunged more than 22% after-hours following topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich... After-Hours Stock Movers: PTC ...

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

Baird analyst Joe Vruwink raised the firm’s price target on PTC (PTC) to $228 from $226 and keeps an Outperform rating on the shares. The firm said management was very forceful that disruption ...

In other PTC news, Director Janice Chaffin sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $171.34 ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $106.7 million in its third quarter. The Warren, New Jersey-based company said it had a loss ...

ROKA -13%.Now read: AcelRx: Ironically, I Misunderstood The... BySeeking Alpha • Sep 26, 2017 Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14 ...